Funding Opportunity RFA-AI-19-004 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for a HIV/AIDS Maternal, Adolescent and Pediatric Therapeutics Clinical Trials Network Leadership and Operations Center (LOC). The LOC will be responsible for the overall administrative and scientific leadership for the HIV/AIDS Maternal, Adolescent and Pediatric Therapeutics Clinical Trials Network.

Funding Opportunity RFA-AI-19-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for a HIV/AIDS Adult Therapeutics Clinical Trials Network Leadership and Operations Center (LOC). The LOC will be responsible for the overall administrative and scientific leadership for the HIV/AIDS Adult Therapeutics Clinical Trials Network.

Funding Opportunity RFA-AI-19-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for HIV/AIDS Clinical Trials Networks Statistical and Data Management Centers (SDMCs). The SDMCs will be responsible for the statistical and data management leadership and coordination critical to the NIAID HIV/AIDS Clinical Trials Networks.

Funding Opportunity PAR-19-170 from the NIH Guide for Grants and Contracts. This purpose of this FOA is to identify risk factors for dementia progression in PDD. Applicants must have access to well-characterized populations of PDD patients that have been followed longitudinally that they can continue to follow with clinical assessments and biospecimen collection until autopsy. Research should propose to identify clinical, pathological and/or biospecimen factors that predict which patients will develop cognitive impairment and/or dementia.

Funding Opportunity RFA-AA-19-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), encourages Research Project Grant (R01) applications proposing to conduct mechanistic studies on the relationships between sleep problems and alcohol dependence. A major impediment for recovery from alcohol use disorder (AUD) is the persistent sleep problems during abstinence promoting relapse. The objective of this FOA is to promote research in animal models and human subjects on the reciprocal relationships between chronic alcohol use and sleep disruptions. The major goal is to understand the underlying mechanisms that will lead to improved treatments for alcohol dependence. NIAAA strongly encourages collaborative efforts between experts in sleep research and established alcohol investigators to facilitate the development of proposals incorporating both areas of research.

Negotiable: SRG: We are looking for a talented Senior Bioinformatician, who can contribute to the development of bioinformatics software to analyse and report out clinically-relevant results generated by the sequencing platform, as well as to assist in the identification London, England

Funding Opportunity RFA-DK-19-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development of targeted mass spectrometric assays (e.g., Multiple Reaction Monitoring) for proteins and peptides of primary interest to the obesity research community (e.g., Adiponectin, Leptin, Resistin, Neuropeptide Y, Alpha-melanocyte-stimulating hormone, Peptide YY, Glucagon-like peptide 1, Ghrelin, Adrenocorticotropin, Corticotropin-releasing hormone, Gastrin, Cholecystokinin, Secretin, Vasoactive intestinal peptide, gastric-inhibitory peptide, gastrin-releasing peptide, motilin, pancreatic polypeptide,RBP4,myostatin, FGF21). The proposed assays should be highly reproducible, easily transferable to other laboratories, easy to multiplex, and validated in human plasma or serum.

Funding Opportunity RFA-DK-18-007 from the NIH Guide for Grants and Contracts. This FOA invites applications for planning cooperative agreements (U34) for a national, multisite, observational cohort study to prospectively examine the risk and protective factors for neurocognitive complications of pediatric type 1 diabetes (T1D; onset approximately ages 5-10 years) and a comparison sample. The U34 is designed to: 1) Permit early peer review of the rationale for the proposed cohort study; 2) Permit assessment of the study design; and 3) Provide support for the development of essential elements required for the design and conduct of the cohort study and the management and analysis of the study data. Consultation with NIDDK scientific staff is strongly encouraged prior to the submission of the U34 application.

Notice NOT-AA-19-005 from the NIH Guide for Grants and Contracts

Experience in Bioinformatics and Genomic Sciences research. Perform and develop routine and complex computational and database methods for implementation....
From Medical College of Wisconsin - Wed, 23 Jan 2019 15:07:48 GMT - View all Milwaukee, WI jobs

Notice NOT-OD-19-047 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-062 from the NIH Guide for Grants and Contracts

Negotiable: Paramount Recruitment: Clinical Bioinformatician Bioinformatics, Permanent, Rare Diseases and Cancer! Paramount are working in partnership with Genomics England who have successfully completed their 100,000 Genomes Project and are now working with the NHS to create the w London, England

Negotiable: Paramount Recruitment: Rare Disease Analyst - Permanent 100,000 Genomes Project - Bioinformatics - Central London Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 Genomes Project. London, England

Notice NOT-AT-19-020 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-167 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages research to develop, characterize and validate innovative mammalian models that recapitulate molecular, cellular, neuropathological, behavioral and cognitive hallmarks of the Alzheimers Disease-Related Dementias (ADRD), including Lewy body dementia (LBD), vascular contributions to cognitive impairment and dementia (VCID), frontotemporal degeneration (FTD) and mixed etiology dementias (MED). Models will be expected to exhibit a broad range of features characteristic of the dementia disorder being modeled, including a mid- to late-life onset consistent with the human disorder, multiple age-dependent neuropathological processes and the associated behavioral, cognitive and/or physiological abnormalities. For each proposed mammalian model, a relevant suite of phenotypes that inform human ADRD disease progression and mechanisms should be characterized across the full life span or, for longer-living mammalian models, throughout the disease-relevant stages of adulthood. The goal of this FOA is to establish multi-dimensional mammalian models for ADRD to serve as tools to interrogate molecular disease mechanisms and identify therapeutic targets.

Notice NOT-HL-19-675 from the NIH Guide for Grants and Contracts

Competitive Salary: Merck (US): Merck Research Labs seeks a postdoc with advanced knowledge of statistical or machine learning for Biostatistics and Research Decision Sciences. Upper Gwynedd, Pennsylvania (US)

Notice NOT-AG-19-001 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AT-19-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to establish a National Center for Natural Product Technology Methodology and Performance Optimization (NP-TEMPO). This initiative is to improve upon and strengthen technologies and methods used in natural products research. The NP-TEMPO, supported through the U41 cooperative agreement funding mechanism, is expected to overcome existing research limitations by developing and/or adapting cutting edge, innovative approaches and technologies that will have significant impact on the chemical and biological annotation of natural products. This FOA is being released in conjunction with the National Center for Complementary and Integrative Health (NCCIH) NMR Open Access Data Exchange and the Office of Dietary Supplements (ODS) Botanical Dietary Supplement Research Centers Program. Collectively, the awards under these FOA constitute the NCCIH/ODS Centers Advancing Research on Botanical and Other Natural Products (CARBON) Program. Applicants applying under this NP-TEMPO FOA are encouraged to collaborate with the NODE, the Botanical Dietary Supplement Research Centers, and other NCCIH, ODS, and NIH supported grantees through NP-TEMPO Technology Demonstration Projects (TDPs).